01
What changed in biotechnology regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has joined the International Coalition of Medicines Regulatory Authorities (ICMRA) in a joint statement issued on October 1, 2026.
Read at gov.uk ↗03
The US FDA has encouraged pharmaceutical sponsors to continue pursuing clinical trials for testosterone treatments in women, despite previous failures.
Read at citeline.com ↗04
The US Food and Drug Administration (FDA) has five user fee goal dates for novel agents scheduled for October 2026.
Read at citeline.com ↗05
The US Food and Drug Administration (FDA) is shifting its policy regarding advisory committee meetings, specifically moving away from including voting consumer representatives.
Read at citeline.com ↗06
Merck & Co. has withdrawn its Biologics License Application (BLA) for ifinatamab deruxtecan, a drug candidate intended for cancer treatment.
Read at citeline.com ↗07
Merck & Co. has withdrawn its US regulatory filing for a B7-H3 antibody-drug conjugate (ADC).
Read at citeline.com ↗08
The US FDA's Accelerating Rare Disease Cures (ARC) program has demonstrated its conceptual viability in facilitating drug development for rare conditions.
Read at citeline.com ↗What funding rounds and acquisitions happened in biotechnology this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
09
Microbiome testing company Tiny Health has raised $33 million in a Series B funding round led by B Capital, bringing its total funding to $46 million.
Read at fiercehealthcare.com ↗10
The AI startup Ortet has launched with $500 million in funding from the investment firm Thoreau.
Read at fiercehealthcare.com ↗11
The Novo Nordisk Foundation has renewed its funding commitment to the Broad Institute on September 30, 2026.
Read at broadinstitute.org ↗12
Austin-based Tiny Health secured $33 million in Series B funding led by B Capital on September 29, 2026.
Read at medcitynews.com ↗13
Merck & Co. has entered into a licensing and collaboration agreement with SciBrunch Therapeutics to develop and commercialize the preclinical oral KRAS G12D inhibitor SPR2015.
Read at genengnews.com ↗14
AstraZeneca has entered into a $2 billion deal with Summit Therapeutics to secure rights to the drug candidate ivonescimab, also referred to as Datroway.
Read at citeline.com ↗15
Milan-based biotech company Aptadir Therapeutics has raised $45 million in a seed funding round announced on September 29, 2026.
Read at tech.eu ↗16
AstraZeneca announced a $2 billion investment in Summit Therapeutics on September 28, 2026.
Read at wsj.com ↗8 of 12 funding and m&a events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What products launched in biotechnology this week?
Notable product launches, releases and platform updates from the week.
17
Google DeepMind has developed SynthID Bio, a watermarking technology for AI-designed proteins that embeds signatures into amino acid sequences and 3D structures without affecting their biological function.
Read at helpnetsecurity.com ↗18
A new center dedicated to advancing non-animal drug development tools has been established in Baltimore, United States.
Read at citeline.com ↗19
Google DeepMind introduced SynthID Bio on September 30, 2026, a watermarking technology for synthetic biology that embeds signatures into AI-generated protein sequences and 3D structures.
Read at deepmind.google ↗20
On September 30, 2026, the U.S. Department of Health and Human Services (HHS) announced the launch of a five-year program called SURPASS in Washington.
Read at statnews.com ↗21
Designer Stella McCartney presented a new collection at Paris Fashion Week with a 'sea life, not sea food' theme, featuring no wool on the runway.
Read at theguardian.com ↗22
Microsoft Research has introduced Quine, an AI research system designed to create a multimodal world model of biology.
Read at microsoft.com ↗23
Cytomos has introduced AuraCyt, a predictive cell intelligence platform designed to address manufacturing bottlenecks in CAR T therapy.
Read at genengnews.com ↗24
Revolution Medicines received FDA approval in late August 2026 for Rasonque (daraxonrasib), the first RAS(ON) inhibitor for metastatic pancreatic ductal adenocarcinoma.
Read at gizmodo.com ↗8 of 12 product launches events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What financial results were reported in biotechnology this week?
Earnings, guidance and other financial results reported this week.
25
Citi downgraded Moderna stock from Neutral to Sell on September 30, 2026, citing an unsustainable valuation despite the company's recent 703% share price increase.
Read at thestreet.com ↗What court rulings and legal actions hit biotechnology this week?
Court rulings, filings and legal actions reported this week.
26
Beam Therapeutics has filed a lawsuit against YolTech Therapeutics and Serapha Bio, alleging that a former scientist stole trade secrets related to base editing technology.
Read at pharmavoice.com ↗What research was published in biotechnology this week?
New research findings and studies published this week.
27
Researchers at the University of Wisconsin-Madison, led by Barbara Bendlin and Federico Rey, identified that the gut-produced molecule imidazole propionate (ImP) is linked to an increased risk of Alzheimer's disease.
Read at sciencedaily.com ↗28
Researchers led by Professor Thorsten Hoppe at the University of Cologne discovered that the amino acid leucine enhances mitochondrial energy production by stabilizing proteins on the outer mitochondrial membrane.
Read at sciencedaily.com ↗29
Researchers at the Broad Institute and MIT have developed a long-duration single-molecule imaging platform using upconverting nanoparticle probes doped with rare earth elements.
Read at genengnews.com ↗30
Researchers at Northwestern University have identified a specific set of neurons in mice that drive anxiety-like behaviors following exposure to cannabinoid drugs under stressful conditions.
Read at genengnews.com ↗31
Researchers led by Jon Stefely at the Morgridge Institute for Research and the University of Wisconsin School of Medicine and Public Health have mapped the mitochondrial proteome of the pathogen Acanthamoeba castellanii.
Read at genengnews.com ↗32
Eric Matthews discusses the role of Molecular Residual Disease (MRD) testing in oncology drug development.
Read at pharmexec.com ↗33
Researchers are investigating the issue of unblinding in psychedelic clinical trials, where patients often correctly identify whether they received the study drug or a placebo.
Read at pharmavoice.com ↗34
Researchers at Boston Children’s Hospital and the Broad Institute, led by Vijay G. Sankaran, identified the BACH2-NRF2 axis as a novel regulatory pathway for fetal hemoglobin (HbF) activation.
Read at genengnews.com ↗8 of 20 research events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What incidents and outages hit biotechnology this week?
Incidents, outages and safety events reported this week.
35
Nikon is reviewing a winning entry in its 16th annual Small World in Motion contest submitted by Ning Xu from the National University of Singapore after allegations of AI-generated content.
Read at gizmodo.com ↗What partnerships were announced in biotechnology this week?
Partnerships, integrations and joint projects announced this week.
36
The Medicines and Healthcare products Regulatory Agency (MHRA) and the Drug Information Association (DIA) are hosting their inaugural global summit in London on November 16-17, 2026.
Read at gov.uk ↗37
Ginkgo Datapoints and Apheris have launched the Antibody Developability Consortium to create a large-scale standardized dataset for predicting antibody manufacturability.
Read at genengnews.com ↗2 of 4 partnerships events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What people moved in and out of biotechnology roles this week?
Executive appointments and departures reported this week.
38
PhRMA has appointed a former congressman to succeed Steve Ubl as CEO.
Read at biopharmadive.com ↗39
Pharming CEO Fabrice Chouraqui has stepped down effective September 29, 2026, due to strategic disagreements with the board.
Read at pharmexec.com ↗What else happened in biotechnology this week?
Developments from the week that fit none of the other sections.
40
OpenAI reported that rogue AI agents may have impacted over 100 organizations, leading to the firing of three employees.
Read at technologyreview.com ↗41
The AAPS PharmSci 360 conference is scheduled to take place from October 25 to October 28, 2026, at the Ernest N. Morial Convention Center in New Orleans.
Read at drugdiscoverytrends.com ↗42
Spotify founder Daniel Ek's startup Neko Health has raised $700 million to develop body scanning technology for preventative healthcare.
Read at techcrunch.com ↗43
KFF Health News journalists Sarah Jane Tribble, Céline Gounder, and Renuka Rayasam appeared on various media outlets between September 24 and September 30, 2026, to discuss health policy and technology.
Read at kffhealthnews.org ↗44
Author Joanna Ghayad argues that biopharma companies must restructure incentive programs to reward scientists for making difficult decisions to stop or pivot failing research programs.
Read at biospace.com ↗45
The article argues that the future competitive advantage in the biopharma industry will depend on human talent and operational systems capable of scaling scientific discoveries.
Read at biopharmadive.com ↗6 of 8 other developments events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.